Biocon Limited

NSEI:BIOCON Stock Report

Market Cap: ₹393.6b

Biocon Future Growth

Future criteria checks 4/6

Biocon is forecast to grow earnings and revenue by 24.4% and 15.6% per annum respectively. EPS is expected to grow by 27.3% per annum. Return on equity is forecast to be 6% in 3 years.

Key information

24.4%

Earnings growth rate

27.3%

EPS growth rate

Biotechs earnings growth44.2%
Revenue growth rate15.6%
Future return on equity6.0%
Analyst coverage

Good

Last updated15 Apr 2025

Recent future growth updates

Biocon Limited Just Missed EPS By 81%: Here's What Analysts Think Will Happen Next

Feb 02
Biocon Limited Just Missed EPS By 81%: Here's What Analysts Think Will Happen Next

Here's What Analysts Are Forecasting For Biocon Limited (NSE:BIOCON) After Its Second-Quarter Results

Nov 02
Here's What Analysts Are Forecasting For Biocon Limited (NSE:BIOCON) After Its Second-Quarter Results

Biocon Limited Just Beat EPS By 240%: Here's What Analysts Think Will Happen Next

Feb 12
Biocon Limited Just Beat EPS By 240%: Here's What Analysts Think Will Happen Next

Recent updates

Biocon Limited's (NSE:BIOCON) Business Is Trailing The Market But Its Shares Aren't

Mar 10
Biocon Limited's (NSE:BIOCON) Business Is Trailing The Market But Its Shares Aren't

Does Biocon (NSE:BIOCON) Have A Healthy Balance Sheet?

Feb 20
Does Biocon (NSE:BIOCON) Have A Healthy Balance Sheet?

Biocon Limited Just Missed EPS By 81%: Here's What Analysts Think Will Happen Next

Feb 02
Biocon Limited Just Missed EPS By 81%: Here's What Analysts Think Will Happen Next

Is Now The Time To Put Biocon (NSE:BIOCON) On Your Watchlist?

Jan 19
Is Now The Time To Put Biocon (NSE:BIOCON) On Your Watchlist?

A Look At The Intrinsic Value Of Biocon Limited (NSE:BIOCON)

Jan 03
A Look At The Intrinsic Value Of Biocon Limited (NSE:BIOCON)
author-image

Tactical Biosimilars Expansion And Viatris Integration Will Propel Revenue Growth And Boost Profitability

Dec 12 Strategic cost improvements and production efficiencies are set to enhance margins and profitability in the generics segment.

Here's What Analysts Are Forecasting For Biocon Limited (NSE:BIOCON) After Its Second-Quarter Results

Nov 02
Here's What Analysts Are Forecasting For Biocon Limited (NSE:BIOCON) After Its Second-Quarter Results

Why Investors Shouldn't Be Surprised By Biocon Limited's (NSE:BIOCON) Low P/E

Nov 01
Why Investors Shouldn't Be Surprised By Biocon Limited's (NSE:BIOCON) Low P/E

Do Biocon's (NSE:BIOCON) Earnings Warrant Your Attention?

Oct 14
Do Biocon's (NSE:BIOCON) Earnings Warrant Your Attention?

These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively

Sep 20
These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively

Biocon Limited's (NSE:BIOCON) Earnings Haven't Escaped The Attention Of Investors

Jun 29
Biocon Limited's (NSE:BIOCON) Earnings Haven't Escaped The Attention Of Investors

Is Biocon (NSE:BIOCON) A Risky Investment?

Jun 11
Is Biocon (NSE:BIOCON) A Risky Investment?

Biocon (NSE:BIOCON) Is Reducing Its Dividend To ₹0.50

Jun 11
Biocon (NSE:BIOCON) Is Reducing Its Dividend To ₹0.50

Biocon's (NSE:BIOCON) Promising Earnings May Rest On Soft Foundations

May 24
Biocon's (NSE:BIOCON) Promising Earnings May Rest On Soft Foundations

Biocon's (NSE:BIOCON) Dividend Is Being Reduced To ₹0.50

May 23
Biocon's (NSE:BIOCON) Dividend Is Being Reduced To ₹0.50

Is Now The Time To Put Biocon (NSE:BIOCON) On Your Watchlist?

Mar 20
Is Now The Time To Put Biocon (NSE:BIOCON) On Your Watchlist?

Biocon Limited Just Beat EPS By 240%: Here's What Analysts Think Will Happen Next

Feb 12
Biocon Limited Just Beat EPS By 240%: Here's What Analysts Think Will Happen Next

Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 18% Below Its Share Price

Jan 23
Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 18% Below Its Share Price

Shareholders Should Be Pleased With Biocon Limited's (NSE:BIOCON) Price

Jan 03
Shareholders Should Be Pleased With Biocon Limited's (NSE:BIOCON) Price

These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively

Nov 13
These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively

Estimating The Intrinsic Value Of Biocon Limited (NSE:BIOCON)

Aug 03
Estimating The Intrinsic Value Of Biocon Limited (NSE:BIOCON)

Biocon (NSE:BIOCON) Will Pay A Larger Dividend Than Last Year At ₹1.50

Jul 03
Biocon (NSE:BIOCON) Will Pay A Larger Dividend Than Last Year At ₹1.50

Is Biocon (NSE:BIOCON) Using Too Much Debt?

Jul 02
Is Biocon (NSE:BIOCON) Using Too Much Debt?

Biocon's (NSE:BIOCON) Dividend Will Be Increased To ₹1.50

May 26
Biocon's (NSE:BIOCON) Dividend Will Be Increased To ₹1.50

Estimating The Fair Value Of Biocon Limited (NSE:BIOCON)

Mar 28
Estimating The Fair Value Of Biocon Limited (NSE:BIOCON)

Here's Why Biocon (NSE:BIOCON) Can Manage Its Debt Responsibly

Feb 26
Here's Why Biocon (NSE:BIOCON) Can Manage Its Debt Responsibly

Biocon Limited (NSE:BIOCON) Shares Could Be 24% Above Their Intrinsic Value Estimate

Dec 17
Biocon Limited (NSE:BIOCON) Shares Could Be 24% Above Their Intrinsic Value Estimate

Earnings and Revenue Growth Forecasts

NSEI:BIOCON - Analysts future estimates and past financials data (INR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/2027206,03014,12327,307N/A14
3/31/2026177,6198,93321,617N/A17
3/31/2025149,8968,39616,062N/A17
12/31/2024147,6188,043N/AN/AN/A
9/30/2024148,94114,39221,04540,368N/A
6/30/2024147,66015,808N/AN/AN/A
3/31/2024147,55710,22510,22329,539N/A
12/31/2023146,12512,002N/AN/AN/A
9/30/2023135,9994,984-6,24111,717N/A
6/30/2023124,5734,197N/AN/AN/A
3/31/2023111,7424,6271,26218,525N/A
12/31/202298,0913,881N/AN/AN/A
9/30/202290,4226,170-6,83611,543N/A
6/30/202285,6297,084N/AN/AN/A
3/31/202281,8406,484-7,48211,766N/A
12/31/202175,8006,727N/AN/AN/A
9/30/202172,6326,542-6,36612,763N/A
6/30/202171,7266,852N/AN/AN/A
3/31/202171,4317,405-5,86611,597N/A
12/31/202068,9135,996N/AN/AN/A
9/30/202067,5716,362-6,57610,484N/A
6/30/202065,7966,870N/AN/AN/A
3/31/202063,0057,771-5,53412,831N/A
12/31/201963,1508,385N/AN/AN/A
9/30/201961,0778,529-3,41614,573N/A
6/30/201958,5659,919N/AN/AN/A
3/31/201955,1449,053-3,37411,546N/A
12/31/201851,5518,220N/AN/AN/A
9/30/201846,7226,967N/AN/AN/A
6/30/201843,1984,108N/AN/AN/A
3/31/201841,2343,724N/A6,621N/A
12/31/201738,7923,695N/AN/AN/A
9/30/201738,5894,489N/AN/AN/A
6/30/201738,3615,268N/AN/AN/A
3/31/201738,9116,121N/A6,400N/A
12/31/201640,48711,633N/AN/AN/A
9/30/201638,11010,961N/AN/AN/A
6/30/201636,5399,388N/AN/AN/A
3/31/201633,4745,504N/A3,706N/A
12/31/201532,9977,367N/AN/AN/A
9/30/201532,3257,247N/AN/AN/A
6/30/201531,5285,207N/AN/AN/A
3/31/201530,8984,974N/A2,107N/A
12/31/201429,8074,091N/AN/AN/A
9/30/201429,1684,231N/AN/AN/A
6/30/201429,0144,232N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BIOCON's forecast earnings growth (24.4% per year) is above the savings rate (6.7%).

Earnings vs Market: BIOCON's earnings (24.4% per year) are forecast to grow faster than the Indian market (17.5% per year).

High Growth Earnings: BIOCON's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: BIOCON's revenue (15.6% per year) is forecast to grow faster than the Indian market (10.2% per year).

High Growth Revenue: BIOCON's revenue (15.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: BIOCON's Return on Equity is forecast to be low in 3 years time (6%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/15 18:20
End of Day Share Price 2025/04/15 00:00
Earnings2024/12/31
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Biocon Limited is covered by 53 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Meeta ShettyAsian Markets Securities Private Limited
Vijayaraghavan SwaminathanAvendus Spark
Harith AhamedAvendus Spark